Offers bioanalytical, biomarker and vaccine
sciences services for global and China-based customers
PPD, Inc. (Nasdaq: PPD), a leading global contract research
organization, held a grand opening ceremony for its new
multipurpose laboratory in Suzhou, China, to support Western and
China-based pharmaceutical and biotech companies managing China
research studies. The 67,000-square-foot facility in the Suzhou New
District, Jiangsu Province, offers bioanalytical, biomarker and
vaccine laboratory services to support trials across all phases of
pharmaceutical development. The company anticipates adding
approximately 300 highly skilled professionals over the next three
years as a result of the expansion. This new lab supplements the
company’s existing Shanghai central lab, established in 2015.
“With our new state-of-the-art operations, the latest
instrumentation and high-throughput automation, we are further
equipped to provide high-quality results and data for our
customers,” said Christopher Fikry, M.D., executive vice president
of PPD® Laboratories. “We can now offer an in-country lab facility
for clinical studies in China that provides the same capabilities
that are available for studies at our other locations around the
world. Through scientific excellence and consistent, high-quality
delivery of critical data, we will help expedite the drug
development process for customers who are either based or doing
business in China.”
PPD celebrated the grand opening of the new lab recently with a
variety of festivities at the facility in Suzhou, including the
traditional Lion Dance, comments from company representatives and
government officials, and a ceremonial ribbon cutting, as well as
tours of the new high-tech operation. Virtual versions of the grand
opening event in English will be held 9 June at 9 a.m. and 12 p.m.
(U.S. Eastern time).
In Suzhou, the bioanalytical lab includes services for small
molecules, biologics, and cell and gene therapies. The lab
encompasses multiple technology platforms across a wide range of
applications, including ligand-binding immunochemistry, liquid
chromatography tandem mass spectrometry (LC-MS/MS), polymerase
chain reaction (PCR) and flow cytometry. The lab also specializes
in the development and validation of fully compliant robust custom
assays for pharmacokinetic/pharmacodynamic (PK/PD) analyses and
immunogenicity assessments in both preclinical and clinical
studies.
The biomarker lab offers a range of services applicable across
multiple regulatory compliance environments and fit-for-purpose
applications. Analysis will be performed with molecular testing,
flow cytometry, ligand binding and LC-MS/MS to support both
preclinical and clinical studies. PPD’s alliance with NeoGenomics
Laboratories enhances its internal capabilities with an extensive
test menu. NeoGenomics operates an oncology-focused clinical trials
testing lab in the same building as the PPD Laboratories’ central
lab in Singapore and has established a similar arrangement in PPD’s
new Suzhou facility.
The vaccine sciences lab provides a full range of testing
services specifically designed for vaccine development trials. The
lab employs immunoassays, cell-based assays and multiplexed
functional assays for vaccine efficacy and molecular assays for
infectious disease monitoring. The lab’s services range from
technology assessment and method development to immunogenicity and
concomitant studies.
In the Asia-Pacific region, PPD also maintains central labs in
Shanghai and Singapore that provide support for global clinical
trials with safety and efficacy testing, custom specimen collection
kits and sample management services. The labs offer high-quality
data across a wide range of technologies and applications for all
phases of pharmaceutical development. The central lab’s innovative
enterprise and information management system, the Preclarus®
central lab database, delivers data in real time to expedite
project teams’ decision-making and help accelerate research. PPD
plans to add central lab services in Suzhou in 2022 to augment the
current capabilities in Shanghai and Singapore.
Reflecting PPD’s ongoing expansion in the China drug development
marketplace, last year the company adopted the Mandarin name Bai
Shi Yi (百�益) for its China-based business. The new name – capturing
the concepts of bai (100), shi (timely) and yi (beneficial) –
reflects PPD’s ambition to ensure 100% customer satisfaction,
accelerate the pace of drug development and help customers deliver
life-changing therapies to patients.
PPD has had a presence in China for more than 20 years, with
operations in Hong Kong, Shanghai, Beijing, Taipei, Guangzhou and
Shenyang. The company employs more than 1,100 professionals in over
70 cities across China.
In addition to the new multi-functional lab in Suzhou, PPD
Laboratories’ global operations include bioanalytical labs in
Middleton, Wisconsin, and Richmond, Virginia; GMP (good
manufacturing practices) labs in Athlone, Ireland, and Middleton;
central labs in Shanghai, Brussels, Belgium, Highland Heights,
Kentucky, and Singapore; biomarker labs in Richmond, Highland
Heights, Belgium and Singapore; and a vaccine sciences lab in
Richmond.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our clients and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With offices in 47 countries and more
than 27,000 professionals worldwide, PPD applies innovative
technologies, therapeutic expertise and a firm commitment to
quality to help clients and partners bend the cost and time curve
of drug development and optimize value in delivering life-changing
therapies to improve health. For more information, visit
www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the planned
acquisition of PPD by Thermo Fisher Scientific Inc.; and other
factors disclosed under the “Risk Factors” section in our periodic
reports filed with the Securities and Exchange Commission (SEC),
including our latest Annual Report on Form 10-K and Quarterly
Report on form 10-Q, which are available on our website at
https://investors.ppd.com or the SEC’s website at www.sec.gov. We
assume no obligation and disclaim any duty to revise or update any
forward-looking statements, or make any new forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210524005476/en/
Media: Randy Buckwalter +1 919 456 4425 media@ppd.com Investors:
Tracy Krumme +1 910 558 4186 investors@ppd.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jun 2023 to Jun 2024